Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chia-Chi Lin

Showing results (71-80 of 231) with videos related to

Pageof 24
Sort By:
Cancer Research and Treatment|May 12, 2017
TAK-264 (MLN0264) in Previously Treated Asian Patients with Advanced Gastrointestinal Carcinoma Expressing Guanylyl Cyclase C: Results from an Open-Label, Non-randomized Phase 1 StudyYung-Jue Bang, Toshimi Takano, Chia-Chi Lin, et al.
Bladder Cancer (Amsterdam, Netherlands)|August 9, 2016
Obesity and Outcomes in Patients with Metastatic Urothelial CarcinomaAmanda Leiter, John Doucette, Susan Krege, et al.
Targeted Oncology|April 12, 2022
Correction to: A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological MalignanciesToshio Shimizu, Yasutoshi Kuboki, Chia-Chi Lin, et al.
Lung Cancer (Amsterdam, Netherlands)|December 3, 2025
Entrectinib in Asian patients with ROS1 fusion-positive non-small cell lung cancer: updated efficacy and safety analysisShun Lu, Yun Fan, Xiaorong Dong, et al.
Anticancer Research|January 30, 2003
A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracilChih-Hung Hsu, Ann-Lii Cheng, Chiun Hsu, et al.
Cancer|May 31, 2013
Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapyMatthew D Galsky, Erin Moshier, Susan Krege, et al.
Anticancer Research|February 16, 2006
Differential expression of molecular markers in arsenic- and non-arsenic-related urothelial cancerTzyh-Chyuan Hour, Yeong-Shiau Pu, Chia-Chi Lin, et al.
Urologic Oncology|May 8, 2007
Weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in hormone-refractory prostate cancer: in vitro combined effects and a phase II trialChia-Chi Lin, Chih-Hung Hsu, Tzyh-Chyuan Hour, et al.
Cancer|May 31, 2013
Relationship between 6- and 9-month progression-free survival and overall survival in patients with metastatic urothelial cancer treated with first-line cisplatin-based chemotherapyMatthew D Galsky, Susan Krege, Chia-Chi Lin, et al.
Targeted Oncology|February 7, 2019
Phase I Study of the Focal Adhesion Kinase Inhibitor BI 853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid TumorsToshihiko Doi, James Chih-Hsin Yang, Kohei Shitara, et al.
Pageof 24

Showing results (71-80 of 231) with videos related to

Sort By:
Pageof 24
Cancer Research and Treatment|May 12, 2017
TAK-264 (MLN0264) in Previously Treated Asian Patients with Advanced Gastrointestinal Carcinoma Expressing Guanylyl Cyclase C: Results from an Open-Label, Non-randomized Phase 1 StudyYung-Jue Bang, Toshimi Takano, Chia-Chi Lin, et al.
Bladder Cancer (Amsterdam, Netherlands)|August 9, 2016
Obesity and Outcomes in Patients with Metastatic Urothelial CarcinomaAmanda Leiter, John Doucette, Susan Krege, et al.
Targeted Oncology|April 12, 2022
Correction to: A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological MalignanciesToshio Shimizu, Yasutoshi Kuboki, Chia-Chi Lin, et al.
Lung Cancer (Amsterdam, Netherlands)|December 3, 2025
Entrectinib in Asian patients with ROS1 fusion-positive non-small cell lung cancer: updated efficacy and safety analysisShun Lu, Yun Fan, Xiaorong Dong, et al.
Anticancer Research|January 30, 2003
A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracilChih-Hung Hsu, Ann-Lii Cheng, Chiun Hsu, et al.
Cancer|May 31, 2013
Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapyMatthew D Galsky, Erin Moshier, Susan Krege, et al.
Anticancer Research|February 16, 2006
Differential expression of molecular markers in arsenic- and non-arsenic-related urothelial cancerTzyh-Chyuan Hour, Yeong-Shiau Pu, Chia-Chi Lin, et al.
Urologic Oncology|May 8, 2007
Weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in hormone-refractory prostate cancer: in vitro combined effects and a phase II trialChia-Chi Lin, Chih-Hung Hsu, Tzyh-Chyuan Hour, et al.
Cancer|May 31, 2013
Relationship between 6- and 9-month progression-free survival and overall survival in patients with metastatic urothelial cancer treated with first-line cisplatin-based chemotherapyMatthew D Galsky, Susan Krege, Chia-Chi Lin, et al.
Targeted Oncology|February 7, 2019
Phase I Study of the Focal Adhesion Kinase Inhibitor BI 853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid TumorsToshihiko Doi, James Chih-Hsin Yang, Kohei Shitara, et al.
Pageof 24